7 research outputs found
Why has not it worked? An empirical application of the extended Burns and Scapens' framework within the implementation of a controlling department
La Interiorización del cambio de un sistema Contable de Gestión en la pequeña empresa
Accounting and Sustainable Development: A Case of Poverty Reduction in an Emerging Economy
Accounting has been widely used in both public and private sectors across the globe for the sustainable development of corporates as well as economies. However, in the recent past, there has been a wide discussion on poverty reduction and public sector accounting reforms especially in emerging economies in order to enhance the transparency in government expenditure, auditing and accountability as well. Since the governments are responsible on providing essential public services which have a greater impact on poverty, adequate measures in place to monitor the spending is vital for any country with an emerging economy. Moreover, according to the United Nations Millennium Development goals (MDGs) especially on reducing poverty, governments may require to recruit more employees for public sector to fill the gaps in the service in many essential areas such as education, health, and agriculture. Additionally, the recent past financial crisis and recession also have impacted on poverty reduction programs within emerging economies especially which are prone to corruption, fraud, and lack of transparency on government expenditures as well. Due to these various reasons, some emerging economies such as that of Sri Lanka are struggling to minimize the huge budget deficit of the government while leaving with less money for poverty reduction within the country as well. Therefore, unless these gaps are filled, many people in emerging economies will continue to live in poverty (Tridico 2009)
The institutionalization of management accounting tools in family firms: the relevance of multiple logics
Candida rugosa Lipase Immobilized onto Acid-Functionalized Multi-walled Carbon Nanotubes for Sustainable Production of Methyl Oleate
Empagliflozin in Patients with Chronic Kidney Disease
Background The effects of empagliflozin in patients with chronic kidney disease who are at risk for disease progression are not well understood. The EMPA-KIDNEY trial was designed to assess the effects of treatment with empagliflozin in a broad range of such patients. Methods We enrolled patients with chronic kidney disease who had an estimated glomerular filtration rate (eGFR) of at least 20 but less than 45 ml per minute per 1.73 m(2) of body-surface area, or who had an eGFR of at least 45 but less than 90 ml per minute per 1.73 m(2) with a urinary albumin-to-creatinine ratio (with albumin measured in milligrams and creatinine measured in grams) of at least 200. Patients were randomly assigned to receive empagliflozin (10 mg once daily) or matching placebo. The primary outcome was a composite of progression of kidney disease (defined as end-stage kidney disease, a sustained decrease in eGFR to < 10 ml per minute per 1.73 m(2), a sustained decrease in eGFR of & GE;40% from baseline, or death from renal causes) or death from cardiovascular causes. Results A total of 6609 patients underwent randomization. During a median of 2.0 years of follow-up, progression of kidney disease or death from cardiovascular causes occurred in 432 of 3304 patients (13.1%) in the empagliflozin group and in 558 of 3305 patients (16.9%) in the placebo group (hazard ratio, 0.72; 95% confidence interval [CI], 0.64 to 0.82; P < 0.001). Results were consistent among patients with or without diabetes and across subgroups defined according to eGFR ranges. The rate of hospitalization from any cause was lower in the empagliflozin group than in the placebo group (hazard ratio, 0.86; 95% CI, 0.78 to 0.95; P=0.003), but there were no significant between-group differences with respect to the composite outcome of hospitalization for heart failure or death from cardiovascular causes (which occurred in 4.0% in the empagliflozin group and 4.6% in the placebo group) or death from any cause (in 4.5% and 5.1%, respectively). The rates of serious adverse events were similar in the two groups. Conclusions Among a wide range of patients with chronic kidney disease who were at risk for disease progression, empagliflozin therapy led to a lower risk of progression of kidney disease or death from cardiovascular causes than placebo